Anshabo, A.T.; Bantie, L.; Diab, S.; Lenjisa, J.; Kebede, A.; Long, Y.; Heinemann, G.; Karanjia, J.; Noll, B.; Basnet, S.K.C.;
et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers 2022, 14, 1113.
https://doi.org/10.3390/cancers14051113
AMA Style
Anshabo AT, Bantie L, Diab S, Lenjisa J, Kebede A, Long Y, Heinemann G, Karanjia J, Noll B, Basnet SKC,
et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers. 2022; 14(5):1113.
https://doi.org/10.3390/cancers14051113
Chicago/Turabian Style
Anshabo, Abel Tesfaye, Laychiluh Bantie, Sarah Diab, Jimma Lenjisa, Alemwork Kebede, Yi Long, Gary Heinemann, Jasmine Karanjia, Benjamin Noll, Sunita K. C. Basnet,
and et al. 2022. "An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia" Cancers 14, no. 5: 1113.
https://doi.org/10.3390/cancers14051113
APA Style
Anshabo, A. T., Bantie, L., Diab, S., Lenjisa, J., Kebede, A., Long, Y., Heinemann, G., Karanjia, J., Noll, B., Basnet, S. K. C., Li, M., Milne, R., Albrecht, H., & Wang, S.
(2022). An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers, 14(5), 1113.
https://doi.org/10.3390/cancers14051113